文献速递复苏、休克与脓毒症心脑血管急症

COVID-19大流行对院外心脏骤停流行病学的影响:系统评价与Meta分析

Impact of the COVID-19 pandemic on the epidemiology of out-of-hospital cardiac arrest: a systematic review and meta-analysis.
PubMed 文献 · Ann Intensive Care · 2021-12-07
一句话结论与疫情前相比,COVID-19大流行期间院外心脏骤停年发病率增加39.5%,病死率上升2.65%,现场终止复苏增加,ROSC、入院存活和出院存活均降低。

该研究系统检索了PubMed、EMBASE、Web of Science、Scopus和Cochrane Library(至2021年5月3日),纳入比较COVID-19大流行期间与历史对照期间院外心脏骤停(OHCA)过程和结局的研究,进行Meta分析。主要结局为年发病率、死亡率和病死率(CFR);次要结局包括现场终止复苏(TOR)、自主循环恢复(ROSC)、入院存活和出院存活,以及临床特征(可除颤心律和病因)。结果显示,大流行期间OHCA汇总年发病率增加39.5%(p<0.001),汇总CFR增加2.65%(p<0.001),死亡率汇总OR为1.95(95%CI 1.51-2.51);现场TOR的OR为2.46(95%CI 1.62-3.74);ROSC的OR为0.65(95%CI 0.55-0.77),入院存活OR为0.65(95%CI 0.48-0.89),出院存活OR为0.52(95%CI 0.40-0.69);可除颤心律减少(OR=0.73,95%CI 0.60-0.88),窒息性病因增加(OR=1.17,95%CI 1.02-1.33)。

要点

  • 大流行期间OHCA汇总年发病率增加39.5%(p<0.001)。
  • 大流行期间OHCA病死率(CFR)增加2.65%(p<0.001),死亡率汇总OR为1.95(95%CI 1.51-2.51)。
  • 大流行期间现场终止复苏(TOR)增加,OR为2.46(95%CI 1.62-3.74)。
  • 大流行期间ROSC(OR=0.65,95%CI 0.55-0.77)、入院存活(OR=0.65,95%CI 0.48-0.89)和出院存活(OR=0.52,95%CI 0.40-0.69)均降低。
  • 大流行期间可除颤心律减少(OR=0.73,95%CI 0.60-0.88),窒息性病因增加(OR=1.17,95%CI 1.02-1.33)。

适用人群与场景

  • 比较COVID-19大流行期间与历史对照期间院外心脏骤停(OHCA)过程和结局的研究人群。

研究设计与关键结果

  • 研究类型为系统评价与Meta分析,检索PubMed、EMBASE、Web of Science、Scopus和Cochrane Library数据库至2021年5月3日,纳入比较OHCA过程与结局在大流行期间与历史对照期间的研究,注册号PROSPERO CRD42021253879。
  • 大流行期间OHCA汇总年发病率增加39.5%(p<0.001)。
  • 大流行期间汇总病死率(CFR)增加2.65%(p<0.001),死亡率汇总OR为1.95(95%CI 1.51-2.51)。
  • 大流行期间现场终止复苏(TOR)增加,OR为2.46(95%CI 1.62-3.74)。
  • 大流行期间ROSC降低(OR=0.65,95%CI 0.55-0.77),入院存活降低(OR=0.65,95%CI 0.48-0.89),出院存活降低(OR=0.52,95%CI 0.40-0.69)。
  • 大流行期间可除颤心律减少(OR=0.73,95%CI 0.60-0.88),窒息性病因增加(OR=1.17,95%CI 1.02-1.33)。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文结论指出,与疫情前相比,COVID-19大流行期间与OHCA发病率增加和结局更差显著相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has significantly influenced epidemiology, yet its impact on out-of-hospital cardiac arrest (OHCA) remains unclear. We aimed to evaluate the impact of the pandemic on the incidence and case fatality rate (CFR) of OHCA. We also evaluated the impact on intermediate outcomes and clinical characteristics.

METHODS: PubMed, EMBASE, Web of Science, Scopus, and Cochrane Library databases were searched from inception to May 3, 2021. Studies were included if they compared OHCA processes and outcomes between the pandemic and historical control time periods. Meta-analyses were performed for primary outcomes [annual incidence, mortality, and case fatality rate (CFR)], secondary outcomes [field termination of resuscitation (TOR), return of spontaneous circulation (ROSC), survival to hospital admission, and survival to hospital discharge], and clinical characteristics (shockable rhythm and etiologies). This study was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42021253879).

RESULTS: The COVID-19 pandemic was associated with a 39.5% increase in pooled annual OHCA incidence (p < 0.001). Pooled CFR was increased by 2.65% (p < 0.001), with a pooled odds ratio (OR) of 1.95 for mortality [95% confidence interval (95%CI) 1.51-2.51]. There was increased field TOR (OR = 2.46, 95%CI 1.62-3.74). There were decreased ROSC (OR = 0.65, 95%CI 0.55-0.77), survival to hospital admission (OR = 0.65, 95%CI 0.48-0.89), and survival to discharge (OR = 0.52, 95%CI 0.40-0.69). There was decreased shockable rhythm (OR = 0.73, 95%CI 0.60-0.88) and increased asphyxial etiology of OHCA (OR = 1.17, 95%CI 1.02-1.33).

CONCLUSION: Compared to the pre-pandemic period, the COVID-19 pandemic period was significantly associated with increased OHCA incidence and worse outcomes.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Teoh SE, Masuda Y, Tan DJH, et al. Impact of the COVID-19 pandemic on the epidemiology of out-of-hospital cardiac arrest: a systematic review and meta-analysis. Ann Intensive Care. 2021. PMID: 34874498. doi:10.1186/s13613-021-00957-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。